Zopf, Dieter
Bayer (Germany)
2 papers on CoChatORCID 0000-0001-9251-7792
Most cited papers
- Verified
Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer
Angiogenesis and VEGF in CancerColorectal Cancer Treatments and Studies
Cited by 1,355
- Verified
Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
Doleschel, D., Hoff, S., Koletnik, S., Rix, A., Zopf, D., Kiessling, F., & Lederle, W. (2021) · Journal of Experimental & Clinical Cancer Research
Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies
Cited by 114
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free